Free Trial

Medpace Q3 2024 Earnings Report

Medpace logo
$340.78 -4.07 (-1.18%)
As of 02/21/2025 03:59 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Medpace EPS Results

Actual EPS
$3.01
Consensus EPS
$2.77
Beat/Miss
Beat by +$0.24
One Year Ago EPS
$2.22

Medpace Revenue Results

Actual Revenue
$533.32 million
Expected Revenue
$540.99 million
Beat/Miss
Missed by -$7.67 million
YoY Revenue Growth
+8.30%

Medpace Announcement Details

Quarter
Q3 2024
Time
After Market Closes

Medpace Earnings Headlines

William Blair Has Bullish Forecast for Medpace Q1 Earnings
Watch This Robotics Demo Before March 17th
Jeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... Just did a demo of what Nvidia’s CEO said will be "the first multitrillion-dollar robotics industry."
What is William Blair's Forecast for Medpace Q3 Earnings?
See More Medpace Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Medpace? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Medpace and other key companies, straight to your email.

About Medpace

Medpace (NASDAQ:MEDP) engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance. The company was founded by August James Troendle in 1992 and is headquartered in Cincinnati, OH.

View Medpace Profile

More Earnings Resources from MarketBeat